Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and damage of the joints. PET/CT imaging is a useful tool for early disease assessment and monitoring treatment efficacy.
Researchers from Lifordi Immunotherapeutics Inc. have developed a novel antibody-drug conjugate (ADC) called LFD-200 that aims to selectively deliver a potent glucocorticoid (GC) payload directly to immune cells. This strategy may potentially offer a new way to treat autoimmune and inflammatory conditions while minimizing systemic toxicity.
Researchers at Ileadbms Co. Ltd. have announced promising results of their novel drug IL-21120033 in a preclinical model of rheumatoid arthritis. The drug acts as a selective agonist of the chemokine receptor CXCR7.
Rheumatoid arthritis, atopic dermatitis, ulcerative colitis and several other inflammatory diseases involve hyperactivation of JAK-STAT signaling, in which the kinase JAK binds and phosphorylates the transcription factor STAT, which then turns on gene expression.
Kymera Therapeutics Inc. has announced a new oral IRF5 degrader program with potential to treat immuno-inflammatory diseases, such as lupus, Sjögren’s syndrome, rheumatoid arthritis and inflammatory bowel disease.
Rheumatoid arthritis (RA) is a chronic autoimmune disorder marked by joint inflammation, cartilage loss and bone damage. Although biological disease-modifying antirheumatic drugs have improved treatment outcomes, the disease remains incurable.
Bristol Myers Squibb Co. has patented new protein-arginine deiminase type-4 (PADI4; PAD4) inhibitors reported to be useful for the treatment of rheumatoid arthritis, among others.
Xi’an Xintong Medicine Research Co. Ltd. has synthesized tyrosine-protein kinase JAK3 inhibitors reported to be useful for the treatment of rheumatoid arthritis, alopecia areata, vitiligo, asthma, chronic obstructive pulmonary disease, cancer and inflammatory bowel disease.
Citryll BV has closed an €85 million (US$89.8 million) series B, enabling it to take CIT-013, an antibody designed to block pathological neutrophil extracellular traps that drive a wide range of immune-mediated inflammatory diseases, into phase IIa development.
